A novel nanoparticle formulation for sustained paclitaxel delivery.

Area of Science:

• Materials Science
• Nanotechnology
• Biomedical Engineering

Background:

• Drug delivery systems are crucial for enhancing therapeutic efficacy.
• Chitosan and glyceryl monooleate (GMO) offer promising properties for nanoparticle formulation.
• Targeted delivery of therapeutics like paclitaxel (PTX) can improve cancer treatment outcomes.

Purpose of the Study:

• To develop a novel nanoparticle drug delivery system using chitosan and glyceryl monooleate (GMO).
• To evaluate the system's potential for delivering various therapeutics, including paclitaxel (PTX).

Main Methods:

• Chitosan/GMO nanoparticles were prepared using a multiple emulsion (o/w/o) solvent evaporation technique.
• Characterization included particle size, surface charge, morphology, drug loading, and encapsulation efficiency.
• In vitro release, cellular uptake, and cytotoxicity assays (MTT) were performed on human breast cancer cells (MDA-MB-231).

Main Results:

• Polycationic nanoparticles (400-700 nm) with high yield (98-100%) and entrapment efficiency were successfully prepared.
• The nanoparticles exhibited a hydrophobic core, hydrophilic coating, positive charge, sustained release, and mucoadhesive properties.
• A fourfold increase in cellular uptake and a 1000-fold reduction in paclitaxel's IC(50) were observed.

Conclusions:

• The developed chitosan/GMO nanoparticle system demonstrates significant potential for drug delivery.
• The formulation allows for lower therapeutic doses of paclitaxel, potentially reducing adverse side effects.
• This novel system offers advantages for the delivery of a wide range of therapeutics.